AIIMS Recalls Two Syringe Batches in Three Weeks; Health Ministry Urged to Investigate
The All-India Institute of Medical Sciences (AIIMS) in New Delhi recalled two separate batches of disposable syringes from different manufacturers within three weeks in May 2026, citing quality concerns. A Rajya Sabha member has written to the Union Health Minister requesting a formal investigation into the recalls, procurement oversight, and potential patient safety impacts. The repeated recalls have raised questions about quality assurance protocols and regulatory frameworks governing medical device supplies in premier public healthcare institutions.
AIIMS New Delhi issued two recall notices for disposable 10 ml syringes with needles in May 2026: the first on May 5 for Batch No. 10DSR243 manufactured by M/s Noble Pharmacare Limited (brand Edgex), and the second on May 26 for Batch No. 260433 from M/s Veekay Surgicals Pvt. Ltd. Both recalls cited quality-related complaints and required immediate return of the products. Rajya Sabha Member Haris Beeran has urged the Union Health Ministry to conduct a detailed investigation into the circumstances leading to the recalls, identify specific defects, assess whether patients were adversely affected, and implement corrective measures. The member emphasized that syringes are critical medical devices for infection control and patient safety, and any quality compromise could expose patients to serious health risks including infection and procedural complications. The back-to-back recalls from different suppliers have prompted scrutiny of procurement oversight, inspection mechanisms, and quality control checks in public healthcare institutions.
What's missing
The article does not specify what the actual quality defects were in either batch, whether any adverse patient events were documented, or what corrective actions the manufacturers or AIIMS have taken since the recalls.
What different sources said
- The HinduCenter
AIIMS recalls two syringe batches over quality concerns in a single month; probe sought
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.